Web18 dic 2024 · Aim . To evaluate the safety issues and adverse effects of using TCHP regimen (docetaxel, carboplatin, trastuzumab, and pertuzumab) versus TCP regimen (docetaxel, carboplatin, and trastuzumab) in older postmenopausal women with nonmetastatic HER2-positive breast cancer. HER2 overexpressed in 20–25% of breast … Web11 mag 2016 · In the primary analysis of the NeoSphere trial, patients given neoadjuvant pertuzumab, trastuzumab, and docetaxel showed a significantly improved pathological …
Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for ...
Web5 giu 2024 · Assess the feasibility of four cycles of neoadjuvant Docetaxel Carboplatin Trastuzumab and Pertuzumab (TCHP) in women with early-stage (local/locally advanced) HER2+ breast cancer with a selective escalation of targeted HER2 directed therapy in the high risk group in the adjuvant setting. Web29 ago 2024 · The efficacy of neoadjuvant therapy can be objectively judged by the pathological complete response (pCR) rate, which has been shown in meta-analyses to predict for long-term survival outcomes [19, 20]. We conducted a retrospective review of cases treated with neoadjuvant TCHP to determine the effect of carboplatin dosing on … ricky walter shiffer 42
Pathologic complete response (pCR) rates after neoadjuvant …
Web8 lug 2024 · TCHP is a four-drug neoadjuvant cancer therapy to help treat early-stage HER2-positive breast cancer. The term neoadjuvant means that a person typically … WebAs part of a neoadjuvant regimen, pertuzumab added to trastuzumab plus docetaxel was shown to significantly increase the rate of pathological … WebTCHP is often given with the goal of cure and administered either before surgery (neoadjuvant therapy) to shrink the size of the tumor, or after surgery (adjuvant therapy) to kill any cancer cells that may be still … ricky walter shiffer facebook